Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma

Chaojie Xu; Dongchen Pei; Yi Liu; Yang Yu; Jinhua Guo; Nan Liu; Zhengjun Kang

doi:10.3389/fonc.2022.818860

Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma

Front Oncol. 2022 Mar 1:12:818860. doi: 10.3389/fonc.2022.818860. eCollection 2022.

Authors

Chaojie Xu¹, Dongchen Pei¹, Yi Liu¹, Yang Yu¹, Jinhua Guo¹, Nan Liu¹, Zhengjun Kang¹

Affiliation

¹ Department of Urology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.

Abstract

Background: The tumor microenvironment (TME) regulates the proliferation and metastasis of solid tumors and the effectiveness of immunotherapy against them. We investigated the prognostic role of TME-related genes based on transcriptomic data of bladder urothelial carcinoma (BLCA) and formulated a prediction model of TME-related signatures.

Methods: Molecular subtypes were identified using the non-negative matrix factorization (NMF) algorithm based on TME-related genes from the TCGA database. TME-related genes with prognostic significance were screened with univariate Cox regression analysis and lasso regression. Nomogram was developed based on risk genes. Receiver operating characteristic (ROC) curve and decision curve analysis (DCA) were used for inner and outer validation of the model. Risk scores (RS) of patients were calculated and divided into high-risk group (HRG) and low-risk group (LRG) to compare the differences in clinical characteristics and PD-L1 treatment responsiveness between HRG and LRG.

Results: We identified two molecular subtypes (C1 and C2) according to the NMF algorithm. There were significant differences in overall survival (OS) (p<0.05), progression-free survival (PFS) (p<0.05), and immune cell infiltration between the two subtypes. A total of eight TME-associated genes (CABP4, ZNF432, BLOC1S3, CXCL11, ANO9, OAS1, FBN2, CEMIP) with independent prognostic significance were screened to build prognostic risk models. Age (p<0.001), grade (p<0.001), and RS (p<0.001) were independent predictors of survival in BLCA patients. The developed RS nomogram was able to predict the prognosis of BLCA patients at 1, 3, and 5 years more potentially than the models of other investigators according to ROC and DCA. RS showed significantly higher values (p = 0.047) in patients with stable disease (SD)/progressive disease (PD) compared to patients with complete response (CR)/partial response (PR).

Conclusions: We successfully clustered and constructed predictive models for TME-associated genes and helped guide immunotherapy strategies.

Keywords: bladder urothelial carcinoma; immunotherapy; non-negative matrix factorization; prognosis; tumor microenvironment.